Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE study of ixekizumab synovial biomarkers in refractory psoriatic arthritis
2021-002478-20Phase 4Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria di Ferrara
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixekizumab in psoriatic arthritis (PsA), sponsored by Azienda Ospedaliero-Universitaria di Ferrara. Primary endpoint: ACR20 response at week 12. Started Oct 2021; status: terminated.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2021-002478-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002478-20.